Grant Awarded to Newcastle University to Research Athersys MultiStem in Machine Perfusion Prior to Kidney Transplantation

CLEVELAND–(BUSINESS WIRE)– Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces that Dr. Samuel Tingle, a surgeon and PhD candidate at Newcastle University in Newcastle upon Tyne, England, has received grant funding from the UK Research and Innovation’s Medical Research…Read More